Telomerase activating compounds and methods of use thereof

• US 9,670,138 B2
• Filed: 11/12/2013
• Issued: 06/06/2017
• Est. Priority Date: 06/04/2007
• Status: Active Grant

• Current Assignee: Ben Gurion University of The Negev
• Original Assignee: Ben Gurion University of The Negev
• Inventors: Priel, Esther
• Primary Examiner(s): Ramachandran, Uma
• Application Number:
  US14/077,989
• Publication Number:
  US 20140142067A1
• Time in Patent Office: 1,302 Days
• Field of Search: 514130, 5142318, 51425211, 514316, 514422, 514648, 514721, 514734, 514735
• CPC Class Codes: A61K 31/03 aromatic
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/055 the aromatic ring being substituted by halogen
• CPC Class Codes: A61K 31/136 having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• CPC Class Codes: A61K 31/66 Phosphorus compounds
• CPC Class Codes: A61K 31/695 Silicon compounds
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 39/00 : General protective or antinoxious agents
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/14 : Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: C07C 215/50 : with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
• CPC Class Codes: C07C 215/80 : containing at least two amino groups bound to the carbon skeleton
• CPC Class Codes: C07C 39/367 : polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
• CPC Class Codes: C07C 43/225 : containing halogen
• CPC Class Codes: C07C 43/23 : containing hydroxy or O-metal groups
• CPC Class Codes: C07D 213/16 : containing only one pyridine ring
• CPC Class Codes: C07D 213/30 : Oxygen atoms
• CPC Class Codes: C07D 295/096 : with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• CPC Class Codes: C07D 295/135 : with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• CPC Class Codes: C07F 9/5022 : Aromatic phosphines (P-C aromatic linkage)

Abstract

The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.

Claims

1. A method of stimulating or increasing telomerase activity in an islet cell or in pancreatic tissue of a subject, said method comprising contacting said islet cell or pancreatic tissue of said subject with an effective amount of a compound represented by the structure of formula I:

2. The method of claim 1, wherein said compound is represented by the structure of formula IV:

3. The method of claim 2, wherein said compound is represented by the structure of formula VI:

4. The method of claim 3, wherein said compound is represented by the structure of formula VII:

5. The method of claim 3, wherein said compound is represented by the structure of formula VIII:

6. The method of claim 3, wherein said compound is represented by the structure of formula IX:

7. The method of claim 3, wherein said compound is represented by the structure of formula X:

8. The method of claim 3, wherein said compound is represented by the structure of formula XI:

9. The method of claim 3, wherein said compound is represented by the structure of formula XII:

10. The method of claim 3, wherein said compound is represented by the structure of formula XIII:

11. The method of claim 1, wherein said compound is represented by the structure of formula XIV:

12. The method of claim 1, wherein said compound is represented by the structure of formula XV:

13. The method of claim 1, wherein said compound is represented by the structure of formula XVI:

14. The method of claim 1, wherein said islet cell or pancreatic tissue is contacted with a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier.

15. The method of claim 1, wherein said subject has diabetes.

16. The method of claim 1, wherein said subject is predisposed to diabetes.

17. A method of stimulating or increasing telomerase activity in an islet cell or in pancreatic tissue of a subject, said method comprising contacting said islet cell or pancreatic tissue of said subject, who has diabetes and is in need of increased telomerase activity, with an effective amount of a compound represented by the structure of formula I:

18. A method of stimulating or increasing telomerase activity in an islet cell or in pancreatic tissue of a subject, said method comprising contacting said islet cell or pancreatic tissue of said subject, who is predisposed to diabetes and in need of increased telomerase activity, with an effective amount of a compound represented by the structure of formula I: